New drug duo aims to reboot immune attack on Hard-to-Treat cancers
NCT ID NCT04457778
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called M6223, which blocks a protein called TIGIT that can turn off immune cells. M6223 was given alone or together with another drug, bintrafusp alfa, to 58 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the combination could help control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M6223 (a drug that blocks TIGIT, a protein on immune cells) and bintrafusp alfa (a drug that targets PD-L1 and TGF-beta)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 58 participants, so it is primarily checking safety and dosing. The drugs may not shrink tumors or may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Next Oncology
San Antonio, Texas, 78229, United States
-
Princess Margaret Cancer Centre
Toronto, Canada
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States